Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | JNJ-87189401 + Pasritamig |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| JNJ-87189401 | JNJ 87189401|JNJ87189401 | CD28 Antibody 12 PSMA Antibody 22 | JNJ-87189401 is a bispecific antibody that targets PSMA on tumor cells and CD28 expressed on T-cells, which potentially induces T-cell activation and tumor cell death in PSMA-expressing tumors (Ann Oncol (2024) 35 (Suppl_2): S1000; NCI Drug Dictionary). | |
| Pasritamig | JNJ78278343|JNJ 78278343|JNJ-78278343 | CD3 Antibody 119 | Pasritamig (JNJ-78278343) is an IgG1 bispecific antibody that targets KLK2 on tumor cells and CD3 on T-lymphocytes, which may lead to T-lymphocyte activation and killing of tumor cells expressing KLK2 (PMID: 40450573). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06095089 | Phase I | JNJ-87189401 + Pasritamig | A Study of JNJ-87189401 Plus JNJ-78278343 for Advanced Prostate Cancer | Recruiting | USA | FRA | 0 |